Allogene Therapeutics, Inc. (NASDAQ:ALLO) Given Average Recommendation of “Moderate Buy” by Analysts

Allogene Therapeutics, Inc. (NASDAQ:ALLO) has been given a consensus recommendation of “Moderate Buy” by the ten brokerages that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $9.73.

Several brokerages recently issued reports on ALLO. William Blair reiterated an “outperform” rating on shares of Allogene Therapeutics in a research note on Thursday, November 14th. Piper Sandler dropped their target price on shares of Allogene Therapeutics from $11.00 to $9.00 and set an “overweight” rating on the stock in a research note on Thursday, November 14th. Finally, HC Wainwright reissued a “buy” rating and set a $9.00 price target on shares of Allogene Therapeutics in a research report on Friday, November 8th.

Insider Buying and Selling

In other news, EVP Zachary Roberts sold 27,199 shares of Allogene Therapeutics stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $1.78, for a total transaction of $48,414.22. Following the transaction, the executive vice president now directly owns 488,054 shares of the company’s stock, valued at $868,736.12. The trade was a 5.28 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Timothy L. Moore sold 14,746 shares of the firm’s stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $1.71, for a total transaction of $25,215.66. Following the sale, the insider now owns 250,713 shares in the company, valued at $428,719.23. The trade was a 5.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 71,067 shares of company stock valued at $131,959 over the last 90 days. Company insiders own 24.30% of the company’s stock.

Institutional Trading of Allogene Therapeutics

Several institutional investors have recently made changes to their positions in the business. Dimensional Fund Advisors LP increased its holdings in Allogene Therapeutics by 24.8% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,550,640 shares of the company’s stock valued at $5,944,000 after acquiring an additional 507,021 shares during the last quarter. Squarepoint Ops LLC purchased a new position in shares of Allogene Therapeutics during the second quarter valued at about $295,000. AQR Capital Management LLC bought a new stake in shares of Allogene Therapeutics in the second quarter worth about $64,000. The Manufacturers Life Insurance Company lifted its position in shares of Allogene Therapeutics by 70.3% in the second quarter. The Manufacturers Life Insurance Company now owns 480,381 shares of the company’s stock worth $1,119,000 after buying an additional 198,231 shares in the last quarter. Finally, Algert Global LLC purchased a new stake in shares of Allogene Therapeutics in the second quarter worth about $35,000. Hedge funds and other institutional investors own 83.63% of the company’s stock.

Allogene Therapeutics Stock Up 1.2 %

NASDAQ ALLO opened at $1.64 on Thursday. The firm has a market capitalization of $343.86 million, a PE ratio of -1.05 and a beta of 0.83. The stock’s 50 day moving average is $2.05 and its 200 day moving average is $2.45. Allogene Therapeutics has a twelve month low of $1.61 and a twelve month high of $5.78.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).